Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of “Buy” from Brokerages

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has been assigned a consensus rating of “Buy” from the eight ratings firms that are covering the company, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $6.63.

Several analysts have recently commented on TSHA shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a research report on Monday, January 6th. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, November 14th. Canaccord Genuity Group raised their target price on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th.

Institutional Trading of Taysha Gene Therapies

Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its position in Taysha Gene Therapies by 23.7% during the third quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock valued at $7,163,000 after purchasing an additional 682,273 shares during the last quarter. Wellington Management Group LLP acquired a new stake in shares of Taysha Gene Therapies in the third quarter worth about $931,000. Charles Schwab Investment Management Inc. lifted its position in shares of Taysha Gene Therapies by 7.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 462,867 shares of the company’s stock worth $930,000 after buying an additional 33,123 shares during the last quarter. Barclays PLC lifted its position in shares of Taysha Gene Therapies by 356.0% in the third quarter. Barclays PLC now owns 247,280 shares of the company’s stock worth $513,000 after buying an additional 193,046 shares during the last quarter. Finally, State Street Corp lifted its position in shares of Taysha Gene Therapies by 4.5% in the third quarter. State Street Corp now owns 3,469,068 shares of the company’s stock worth $6,973,000 after buying an additional 150,647 shares during the last quarter. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Stock Performance

Shares of NASDAQ TSHA opened at $1.62 on Friday. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $332.00 million, a price-to-earnings ratio of 2.57 and a beta of 0.92. The stock’s fifty day simple moving average is $1.81 and its 200 day simple moving average is $2.02. Taysha Gene Therapies has a 52-week low of $1.19 and a 52-week high of $4.32.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.